-transparent.png){kind=logo}
In June 1981 the authors activated a trial to evaluate the therapeutic effectiveness of the combination mitomycin C (MMC) + etoposide (VP 16) in previously untreated gastric carcinoma with measurable neoplastic lesions. Drugs were administered according to the following schedule: MMC, 12 mg/m2 i.v. day 1, + VP 16, 150-200 mg/m2 orally days 2, 3, 4, 22, 23, 24 every 6 weeks. The response rate (CR+PR) was 16.7%, which is not higher than that obtained when MMC and VP 16 are used as single agents. Overall median survival (8 months) was similar to that reported in the recent literature with combination chemotherapy.
Related Publications
M Tomirotti, and
F Lombardi, and
R Biasioli, and
R Riundi, and
A Scanni
January 1999,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Tomirotti, and
F Lombardi, and
R Biasioli, and
R Riundi, and
A Scanni
January 1987,
The Korean journal of internal medicine,
M Tomirotti, and
F Lombardi, and
R Biasioli, and
R Riundi, and
A Scanni
August 1989,
Nihon Gan Chiryo Gakkai shi,
M Tomirotti, and
F Lombardi, and
R Biasioli, and
R Riundi, and
A Scanni
July 1986,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Tomirotti, and
F Lombardi, and
R Biasioli, and
R Riundi, and
A Scanni
April 1983,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Tomirotti, and
F Lombardi, and
R Biasioli, and
R Riundi, and
A Scanni
January 1980,
Acta radiologica. Oncology,
M Tomirotti, and
F Lombardi, and
R Biasioli, and
R Riundi, and
A Scanni
October 1999,
Gynecologic oncology,
M Tomirotti, and
F Lombardi, and
R Biasioli, and
R Riundi, and
A Scanni
January 2007,
Chemotherapy,
M Tomirotti, and
F Lombardi, and
R Biasioli, and
R Riundi, and
A Scanni
January 2001,
Voprosy onkologii,
M Tomirotti, and
F Lombardi, and
R Biasioli, and
R Riundi, and
A Scanni
January 1982,
Cancer chemotherapy and pharmacology,
